Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 HFOV vs CV (all trials), Outcome 1 Death by 28‐30 days.
Figuras y tablas -
Analysis 1.1

Comparison 1 HFOV vs CV (all trials), Outcome 1 Death by 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 2 Mechanical ventilation at 28 ‐ 30 days in survivors.
Figuras y tablas -
Analysis 1.2

Comparison 1 HFOV vs CV (all trials), Outcome 2 Mechanical ventilation at 28 ‐ 30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 3 Oxygen at 28‐30 days in survivors.
Figuras y tablas -
Analysis 1.3

Comparison 1 HFOV vs CV (all trials), Outcome 3 Oxygen at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.
Figuras y tablas -
Analysis 1.4

Comparison 1 HFOV vs CV (all trials), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 5 Death or CLD at 28‐30 days.
Figuras y tablas -
Analysis 1.5

Comparison 1 HFOV vs CV (all trials), Outcome 5 Death or CLD at 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 6 Death by 36‐37 weeks or discharge.
Figuras y tablas -
Analysis 1.6

Comparison 1 HFOV vs CV (all trials), Outcome 6 Death by 36‐37 weeks or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.
Figuras y tablas -
Analysis 1.7

Comparison 1 HFOV vs CV (all trials), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.
Figuras y tablas -
Analysis 1.8

Comparison 1 HFOV vs CV (all trials), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 9 Any pulmonary air leak.
Figuras y tablas -
Analysis 1.9

Comparison 1 HFOV vs CV (all trials), Outcome 9 Any pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 10 Gross pulmonary air leak.
Figuras y tablas -
Analysis 1.10

Comparison 1 HFOV vs CV (all trials), Outcome 10 Gross pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 11 Intraventricular hemorrhage ‐ all grades.
Figuras y tablas -
Analysis 1.11

Comparison 1 HFOV vs CV (all trials), Outcome 11 Intraventricular hemorrhage ‐ all grades.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.
Figuras y tablas -
Analysis 1.12

Comparison 1 HFOV vs CV (all trials), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 13 Periventricular leukomalacia.
Figuras y tablas -
Analysis 1.13

Comparison 1 HFOV vs CV (all trials), Outcome 13 Periventricular leukomalacia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.
Figuras y tablas -
Analysis 1.14

Comparison 1 HFOV vs CV (all trials), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 HFOV vs CV (all trials), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.
Figuras y tablas -
Analysis 1.15

Comparison 1 HFOV vs CV (all trials), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 1 Death by 28‐30 days.
Figuras y tablas -
Analysis 2.1

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 1 Death by 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.
Figuras y tablas -
Analysis 2.2

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 3 Oxygen at 28‐30 days in survivors.
Figuras y tablas -
Analysis 2.3

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 3 Oxygen at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.
Figuras y tablas -
Analysis 2.4

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 5 Death or CLD at 28‐30 days.
Figuras y tablas -
Analysis 2.5

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 5 Death or CLD at 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 6 Death by 36‐37 weeks or discharge.
Figuras y tablas -
Analysis 2.6

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 6 Death by 36‐37 weeks or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.
Figuras y tablas -
Analysis 2.7

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.
Figuras y tablas -
Analysis 2.8

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 9 Any pulmonary air leak.
Figuras y tablas -
Analysis 2.9

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 9 Any pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 10 Gross pulmonary air leak.
Figuras y tablas -
Analysis 2.10

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 10 Gross pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 11 Intraventricular hemorrhage ‐ all grades.
Figuras y tablas -
Analysis 2.11

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 11 Intraventricular hemorrhage ‐ all grades.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.
Figuras y tablas -
Analysis 2.12

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 13 Periventricular leukomalacia.
Figuras y tablas -
Analysis 2.13

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 13 Periventricular leukomalacia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.
Figuras y tablas -
Analysis 2.14

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.
Figuras y tablas -
Analysis 2.15

Comparison 2 HFOV vs CV (with volume recruitment), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 1 Death by 28‐30 days.
Figuras y tablas -
Analysis 3.1

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 1 Death by 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.
Figuras y tablas -
Analysis 3.2

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.
Figuras y tablas -
Analysis 3.4

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 5 Death or CLD at 28‐30 days.
Figuras y tablas -
Analysis 3.5

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 5 Death or CLD at 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 6 Death by 36‐37 weeks.
Figuras y tablas -
Analysis 3.6

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 6 Death by 36‐37 weeks.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.
Figuras y tablas -
Analysis 3.7

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.
Figuras y tablas -
Analysis 3.8

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 9 Any pulmonary air leak.
Figuras y tablas -
Analysis 3.9

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 9 Any pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 10 Gross pulmonary air leak.
Figuras y tablas -
Analysis 3.10

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 10 Gross pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 11 Intraventricular hemorrhage ‐ all grades.
Figuras y tablas -
Analysis 3.11

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 11 Intraventricular hemorrhage ‐ all grades.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.
Figuras y tablas -
Analysis 3.12

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 13 Periventricular leukomalacia.
Figuras y tablas -
Analysis 3.13

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 13 Periventricular leukomalacia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 14 Retinopathy of prematurity (mod. or severe) in survivors.
Figuras y tablas -
Analysis 3.14

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 14 Retinopathy of prematurity (mod. or severe) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 15 Neurodevelopmental abnormality at follow up in those examined.
Figuras y tablas -
Analysis 3.15

Comparison 3 HFOV vs CV (without volume recruitment), Outcome 15 Neurodevelopmental abnormality at follow up in those examined.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 1 Death by 28‐30 days.
Figuras y tablas -
Analysis 4.1

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 1 Death by 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.
Figuras y tablas -
Analysis 4.2

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 3 Oxygen at 28‐30 days in survivors.
Figuras y tablas -
Analysis 4.3

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 3 Oxygen at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.
Figuras y tablas -
Analysis 4.4

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 5 Death or CLD at 28‐30 days.
Figuras y tablas -
Analysis 4.5

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 5 Death or CLD at 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 6 Death by 36‐37 weeks or discharge.
Figuras y tablas -
Analysis 4.6

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 6 Death by 36‐37 weeks or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.
Figuras y tablas -
Analysis 4.7

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.
Figuras y tablas -
Analysis 4.8

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 9 Any pulmonary air leak.
Figuras y tablas -
Analysis 4.9

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 9 Any pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 10 Gross pulmonary air leak.
Figuras y tablas -
Analysis 4.10

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 10 Gross pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 11 Intraventricular hemorrhage ‐ all grades.
Figuras y tablas -
Analysis 4.11

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 11 Intraventricular hemorrhage ‐ all grades.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.
Figuras y tablas -
Analysis 4.12

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 13 Periventricular leukomalacia.
Figuras y tablas -
Analysis 4.13

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 13 Periventricular leukomalacia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.
Figuras y tablas -
Analysis 4.14

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 14 Retinopathy of prematurity (grd 2 or more) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.
Figuras y tablas -
Analysis 4.15

Comparison 4 HFOV vs CV (with routine surfactant), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 1 Death by 28‐30 days.
Figuras y tablas -
Analysis 5.1

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 1 Death by 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.
Figuras y tablas -
Analysis 5.2

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 2 Mechanical ventilation at 28‐30 days in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.
Figuras y tablas -
Analysis 5.4

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 4 CLD at 28‐30 days (O2 + xray) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 5 Death or CLD at 28‐30 days.
Figuras y tablas -
Analysis 5.5

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 5 Death or CLD at 28‐30 days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 6 Death by 36‐37 weeks.
Figuras y tablas -
Analysis 5.6

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 6 Death by 36‐37 weeks.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.
Figuras y tablas -
Analysis 5.7

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 7 CLD at 36‐37 weeks PMA or discharge in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.
Figuras y tablas -
Analysis 5.8

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 8 Death or CLD at 36‐37 weeks PMA or discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 9 Any pulmonary air leak.
Figuras y tablas -
Analysis 5.9

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 9 Any pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 10 Gross pulmonary air leak.
Figuras y tablas -
Analysis 5.10

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 10 Gross pulmonary air leak.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 11 Intraventricular hemorrhage ‐ all grades.
Figuras y tablas -
Analysis 5.11

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 11 Intraventricular hemorrhage ‐ all grades.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.
Figuras y tablas -
Analysis 5.12

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 12 Intraventricular hemorrhage ‐ grd 3 or 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 13 Periventricular leukomalacia.
Figuras y tablas -
Analysis 5.13

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 13 Periventricular leukomalacia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 14 Retinopathy of prematurity (mod. or severe) in survivors.
Figuras y tablas -
Analysis 5.14

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 14 Retinopathy of prematurity (mod. or severe) in survivors.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.
Figuras y tablas -
Analysis 5.15

Comparison 5 HFOV vs CV (without routine surfactant), Outcome 15 Neurodevelopmental abnormality at 1‐3 yrs in those examined.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. HFOV vs CV (all trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death by 28‐30 days Show forest plot

8

1853

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.86, 1.35]

2 Mechanical ventilation at 28 ‐ 30 days in survivors Show forest plot

3

767

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.86, 1.35]

3 Oxygen at 28‐30 days in survivors Show forest plot

5

870

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.83, 1.09]

4 CLD at 28‐30 days (O2 + xray) in survivors Show forest plot

4

820

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.74, 1.01]

5 Death or CLD at 28‐30 days Show forest plot

4

955

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.80, 1.01]

6 Death by 36‐37 weeks or discharge Show forest plot

9

2479

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.83, 1.16]

7 CLD at 36‐37 weeks PMA or discharge in survivors Show forest plot

9

2026

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.79, 0.99]

8 Death or CLD at 36‐37 weeks PMA or discharge Show forest plot

9

2479

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.85, 1.00]

9 Any pulmonary air leak Show forest plot

9

2473

Risk Ratio (M‐H, Fixed, 95% CI)

1.14 [1.00, 1.29]

10 Gross pulmonary air leak Show forest plot

7

1557

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.93, 1.67]

11 Intraventricular hemorrhage ‐ all grades Show forest plot

10

2971

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.96, 1.15]

12 Intraventricular hemorrhage ‐ grd 3 or 4 Show forest plot

11

3244

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.95, 1.31]

13 Periventricular leukomalacia Show forest plot

10

3179

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.84, 1.44]

14 Retinopathy of prematurity (grd 2 or more) in survivors Show forest plot

7

2240

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.74, 1.01]

15 Neurodevelopmental abnormality at 1‐3 yrs in those examined Show forest plot

2

477

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.01, 1.58]
Figuras y tablas -
Comparison 1. HFOV vs CV (all trials)
Ir a la tabla de la revisión
Comparison 2. HFOV vs CV (with volume recruitment)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death by 28‐30 days Show forest plot

7

1180

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.80, 1.50]

2 Mechanical ventilation at 28‐30 days in survivors Show forest plot

2

214

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.58, 1.70]

3 Oxygen at 28‐30 days in survivors Show forest plot

5

870

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.83, 1.09]

4 CLD at 28‐30 days (O2 + xray) in survivors Show forest plot

3

267

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.36, 0.76]

5 Death or CLD at 28‐30 days Show forest plot

3

282

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.40, 0.77]

6 Death by 36‐37 weeks or discharge Show forest plot

8

2383

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.83, 1.16]

7 CLD at 36‐37 weeks PMA or discharge in survivors Show forest plot

8

1939

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.79, 0.99]

8 Death or CLD at 36‐37 weeks PMA or discharge Show forest plot

8

2383

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.85, 1.00]

9 Any pulmonary air leak Show forest plot

7

1704

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.91, 1.33]

10 Gross pulmonary air leak Show forest plot

6

1461

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [0.95, 1.74]

11 Intraventricular hemorrhage ‐ all grades Show forest plot

8

2202

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.91, 1.13]

12 Intraventricular hemorrhage ‐ grd 3 or 4 Show forest plot

10

2477

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.20]

13 Periventricular leukomalacia Show forest plot

8

2408

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.65, 1.26]

14 Retinopathy of prematurity (grd 2 or more) in survivors Show forest plot

6

1687

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.68, 0.98]

15 Neurodevelopmental abnormality at 1‐3 yrs in those examined Show forest plot

1

91

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.26, 3.68]
Figuras y tablas -
Comparison 2. HFOV vs CV (with volume recruitment)
Ir a la tabla de la revisión
Comparison 3. HFOV vs CV (without volume recruitment)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death by 28‐30 days Show forest plot

1

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.77, 1.46]

2 Mechanical ventilation at 28‐30 days in survivors Show forest plot

1

553

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.86, 1.41]

3 Oxygen at 28‐30 days in survivors

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 CLD at 28‐30 days (O2 + xray) in survivors Show forest plot

1

553

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.83, 1.17]

5 Death or CLD at 28‐30 days Show forest plot

1

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.88, 1.14]

6 Death by 36‐37 weeks Show forest plot

1

96

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [0.39, 4.75]

7 CLD at 36‐37 weeks PMA or discharge in survivors Show forest plot

1

87

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Death or CLD at 36‐37 weeks PMA or discharge Show forest plot

1

96

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [0.39, 4.75]

9 Any pulmonary air leak Show forest plot

2

769

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [1.00, 1.42]

10 Gross pulmonary air leak Show forest plot

1

96

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.17, 2.58]

11 Intraventricular hemorrhage ‐ all grades Show forest plot

2

769

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.99, 1.37]

12 Intraventricular hemorrhage ‐ grd 3 or 4 Show forest plot

2

769

Risk Ratio (M‐H, Fixed, 95% CI)

1.45 [1.09, 1.93]

13 Periventricular leukomalacia Show forest plot

2

769

Risk Ratio (M‐H, Fixed, 95% CI)

1.64 [1.02, 2.64]

14 Retinopathy of prematurity (mod. or severe) in survivors Show forest plot

1

553

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.74, 1.31]

15 Neurodevelopmental abnormality at follow up in those examined Show forest plot

1

386

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [1.02, 1.60]
Figuras y tablas -
Comparison 3. HFOV vs CV (without volume recruitment)
Ir a la tabla de la revisión
Comparison 4. HFOV vs CV (with routine surfactant)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death by 28‐30 days Show forest plot

6

1115

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.80, 1.53]

2 Mechanical ventilation at 28‐30 days in survivors Show forest plot

2

214

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.58, 1.70]

3 Oxygen at 28‐30 days in survivors Show forest plot

5

870

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.83, 1.09]

4 CLD at 28‐30 days (O2 + xray) in survivors Show forest plot

2

214

Risk Ratio (M‐H, Fixed, 95% CI)

0.57 [0.35, 0.93]

5 Death or CLD at 28‐30 days Show forest plot

2

217

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.33, 0.87]

6 Death by 36‐37 weeks or discharge Show forest plot

8

2414

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.83, 1.16]

7 CLD at 36‐37 weeks PMA or discharge in survivors Show forest plot

8

1975

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.81, 1.01]

8 Death or CLD at 36‐37 weeks PMA or discharge Show forest plot

8

2414

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.86, 1.02]

9 Any pulmonary air leak Show forest plot

7

1735

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.89, 1.31]

10 Gross pulmonary air leak Show forest plot

6

1492

Risk Ratio (M‐H, Fixed, 95% CI)

1.23 [0.89, 1.70]

11 Intraventricular hemorrhage ‐ all grades Show forest plot

8

2233

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.91, 1.13]

12 Intraventricular hemorrhage ‐ grd 3 or 4 Show forest plot

9

2506

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.82, 1.24]

13 Periventricular leukomalacia Show forest plot

9

2506

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.66, 1.28]

14 Retinopathy of prematurity (grd 2 or more) in survivors Show forest plot

6

1687

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.68, 0.98]

15 Neurodevelopmental abnormality at 1‐3 yrs in those examined Show forest plot

1

91

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.26, 3.68]
Figuras y tablas -
Comparison 4. HFOV vs CV (with routine surfactant)
Ir a la tabla de la revisión
Comparison 5. HFOV vs CV (without routine surfactant)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death by 28‐30 days Show forest plot

2

738

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.78, 1.44]

2 Mechanical ventilation at 28‐30 days in survivors Show forest plot

1

553

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.86, 1.41]

3 Oxygen at 28‐30 days in survivors

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 CLD at 28‐30 days (O2 + xray) in survivors Show forest plot

2

606

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.78, 1.08]

5 Death or CLD at 28‐30 days Show forest plot

2

738

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.84, 1.08]

6 Death by 36‐37 weeks Show forest plot

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.40, 2.58]

7 CLD at 36‐37 weeks PMA or discharge in survivors Show forest plot

1

51

Risk Ratio (M‐H, Fixed, 95% CI)

0.23 [0.07, 0.73]

8 Death or CLD at 36‐37 weeks PMA or discharge Show forest plot

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.52 [0.29, 0.94]

9 Any pulmonary air leak Show forest plot

2

738

Risk Ratio (M‐H, Fixed, 95% CI)

1.21 [1.02, 1.44]

10 Gross pulmonary air leak Show forest plot

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

1.32 [0.65, 2.71]

11 Intraventricular hemorrhage ‐ all grades Show forest plot

2

738

Risk Ratio (M‐H, Fixed, 95% CI)

1.15 [0.98, 1.35]

12 Intraventricular hemorrhage ‐ grd 3 or 4 Show forest plot

2

738

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [1.03, 1.79]

13 Periventricular leukomalacia Show forest plot

1

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [0.99, 2.60]

14 Retinopathy of prematurity (mod. or severe) in survivors Show forest plot

1

553

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.74, 1.31]

15 Neurodevelopmental abnormality at 1‐3 yrs in those examined Show forest plot

1

386

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [1.02, 1.60]
Figuras y tablas -
Comparison 5. HFOV vs CV (without routine surfactant)
Ir a la tabla de la revisión